ArticleBMC cancer2021
Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Squalene Epoxidase: Its Regulations and Links with Cancers.International journal of molecular sciences · 2024Pooled it
- MicNet: integrating spatially resolved transcriptomes and pathology images by contrastive deep neural network.Genome biology · 2026Article
- Squalene Epoxidase: A Key Enzymatic Component in the Triterpenoid Biosynthesis Pathway.Applied biochemistry and biotechnology · 2026Review
- Multi-cohort analysis and experimental study on the function of squalene epoxidase as a ferroptosis inhibitor in HCC.BMC cancer · 2025Article
- Targeting SQLE-mediated cholesterol metabolism to enhance CD8Journal for immunotherapy of cancer · 2025Article
- Ginsenoside 20(S)-Rg3 upregulates SQLE to reprogram cholesterol metabolism of ovarian cancer cells.iScience · 2025Article
- FOXM1 boosts glycolysis by upregulating SQLE to inhibit anoikis in breast cancer cells.Journal of cancer research and clinical oncology · 2025Article
- Cancer-associated fibroblast-secreted exosomal miR-454-3p inhibits lipid metabolism and ferroptosis in breast cancer by targeting ACSL4.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.Molecular cancer · 2025Review
- Characterization of immune landscape and prognostic value of IL-17-related signature in invasive breast cancer.Translational cancer research · 2025Article
- Current Status of Breast Cancer Immunotherapy and Prognosis-Related Markers.Breast cancer (Dove Medical Press) · 2025Review
- A Review Unveiling the Ferroptosis-Regulated Cell Signalling Pathways in Breast Cancer to Elucidate Potent Targets for Cancer Management.Current pharmaceutical design · 2025Review
- Cross-talk between cuproptosis and ferroptosis to identify immune landscape in cervical cancer for mRNA vaccines development.European journal of medical research · 2024Article
- Stabilization of SQLE mRNA by WTAP/FTO/IGF2BP3-dependent manner in HGSOC: implications for metabolism, stemness, and progression.Cell death & disease · 2024Article
- SPDYC serves as a prognostic biomarker related to lipid metabolism and the immune microenvironment in breast cancer.Immunologic research · 2024Article
- Squalene monooxygenase (SQLE) protects ovarian cancer cells from ferroptosis.Scientific reports · 2024Article
- Identification of TFR2 as a novel ferroptosis‑related gene that serves an important role in prognosis and progression of triple‑negative breast cancer.Oncology letters · 2024Article
- Comprehensive Analysis of Angiogenesis and Ferroptosis Genes for Predicting the Survival Outcome and Immunotherapy Response of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
- Unveiling the role of TGF-β signaling pathway in breast cancer prognosis and immunotherapy.Frontiers in oncology · 2024Article
- Construction and evaluation of a multifactorial clinical model for discriminating benign and malignant breast tumors using LASSO algorithm based on retrospective cohort study.American journal of cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFerroptosis, a new form of programmed cell death, has great potential for cancer treatment. However, the roles of ferroptosis-related (FR) genes in breast cancer (BC) remain elusive. MATERIALS AND
methodsUsing TCGA database, a novel FR risk signature was constructed through the Lasso regression analysis. Meanwhile, its prognostic value was assessed by a series of survival analyses. Besides, a nomogram was constructed to predict the overall survival rate (OSR) of individual at 1,3,5 year. Four validation cohorts (n = 2248), including METABRIC, GSE58812, GSE20685 and ICGC-KR datasets, were employed to test the prognostic value of FR risk signature. The effects of FR risk signature on BC immune microenvironment were explored by CIBERSORT algorithm and ssGSEA method. The histological expressions of FR risk genes were presented by HPA database. The biofunctions of SQLE were determined by qPCR, MTT, wound-healing and Transwell assays.
resultsWe constructed a novel FR risk signature consisting of eight genes. High FR risk led a poor prognosis and was identified as an independent prognostic factor. Besides, A higher proportion of patients with luminal A type was observed in low-risk group (53%), while a higher proportion of patients with basal type in high-risk group (24%). FR risk score could discriminate the prognostic difference of most clinical subgroups, except for M1 stage, HER2 and basal types. Moreover, its prognostic value was successfully validated in other four cohorts. Through immune analyses, we found that the reduced infiltration levels of CD8+ and NK cells, whereas the enhanced activity of antigen presentation process appeared in high FR risk. Then, FR risk score was found to weakly correlate with the expressions of six immune checkpoints. Through the experiments in vitro, we confirmed that overexpression of SQLE could promote, whereas blocking SQLE could inhibit the proliferative, migrative and invasive abilities of BC cells.
conclusionsFR risk signature was conducive to BC prognostic assessment. High FR risk level was closely associated with BC immunosuppression, but may not predict ICIs efficacy. Moreover, SQLE was identified as a crucial cancer-promoting gene in BC. Our findings provide new insights into prognostic assessment and molecular mechanism of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.